Australian Clinical Labs (ASX:ACL) 3-Year EBITDA Growth Rate : -11.30% (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Australian Clinical Labs 3-Year EBITDA Growth Rate?

Australian Clinical Labs's EBITDA per Share for the six months ended in Jun. 2024 was A$0.48.

During the past 12 months, Australian Clinical Labs's average EBITDA Per Share Growth Rate was -2.00% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -11.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Australian Clinical Labs was -11.30% per year. The lowest was -11.30% per year. And the median was -11.30% per year.

Competitive Comparison of Australian Clinical Labs's 3-Year EBITDA Growth Rate

For the Diagnostics & Research subindustry, Australian Clinical Labs's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Australian Clinical Labs's 3-Year EBITDA Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Australian Clinical Labs's 3-Year EBITDA Growth Rate falls into.

Australian Clinical Labs 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Australian Clinical Labs (ASX:ACL) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Australian Clinical Labs 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Australian Clinical Labs's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Australian Clinical Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Australian Clinical Labs Ltd (ASX:ACL) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

1868-1892 Dandenong Road, Clayton, VIC, AUS, 3168

Website

https://www.clinicallabs.com.au

Australian Clinical Labs, or ACL, is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well-established in the states of Western Australia, South Australia, Victoria and the Northern Territory.

Australian Clinical Labs Headlines

No Headlines